Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication.
DNAzyme (Dz) molecules have been shown to be highly efficient inhibitors of virus replication. Hepatitis C virus RNA translation is mediated by an internal ribosome entry site (IRES) element located mostly in the 5' untranslated region (UTR), the mechanism of which is fundamentally different from cap-dependent translation of cellular mRNAs, and thus an attractive target for designing antiviral drugs. Inhibition of HCV IRES-mediated translation has drastic consequences for the replication of viral RNA as well. We have designed several Dzs, targeting different regions of HCV IRES specific for 1b and also sequences conserved across genotypes. The RNA cleavage and translation inhibitory activities of these molecules were tested in a cell-free system and in cell culture using transient transfections. The majority of Dzs efficiently inhibited HCV IRES-mediated translation. However, these Dz molecules did not show significant inhibition of coxsackievirus B3 IRES-mediated translation or cap-dependent translation of reporter gene, showing high level of specificity towards target RNA. Also, Northern blot hybridization analysis showed significant cleavage of HCV IRES by the Dz molecules in Huh7 cells transiently transfected with the HCV-FLuc monocistronic construct. Interestingly, one of the Dzs was more effective against genotype1b, whereas the other showed significant inhibition of viral RNA replication in Huh7 cells harbouring a HCV 2a monocistronic replicon. As expected, mutant-Dz failed to cleave RNA and inhibit HCV RNA translation, showing the specificity of inhibition. Taken together, these findings suggest that the Dz molecule can be used as selective and effective inhibitor of HCV RNA replication, which can be explored further for development of a potent therapeutic agent against HCV infection.
Roy
Swagata
S
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore-560012, India.
Gupta
Nidhi
N
National Institute of Immunology, Department of Virology, New Delhi-110067, India.
Subramanian
Nithya
N
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore-560012, India.
Mondal
Tanmoy
T
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore-560012, India.
Banerjea
Akhil Chandra
AC
National Institute of Immunology, Department of Virology, New Delhi-110067, India.
Das
Saumitra
S
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore-560012, India.
D000998:Antiviral Agents / Q000494:pharmacology*; D001483:Base Sequence; D015152:Blotting, Northern; D002460:Cell Line; D021881:DNA, Catalytic / Q000378:metabolism* / Q000494:pharmacology*; D029822:Enterovirus B, Human / Q000187:drug effects; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008969:Molecular Sequence Data; D009690:Nucleic Acid Conformation; D014176:Protein Biosynthesis / Q000187:drug effects; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism*; D014764:Viral Proteins / Q000096:biosynthesis; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D021881:DNA, Catalytic; D012367:RNA, Viral; D014764:Viral Proteins